Galmed Pharmaceuticals
GLMD
16 hedge funds and large institutions have $71.2K invested in Galmed Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.
1.83% less ownership
Funds ownership: 4.05% → 2.21% (-1.8%)
6% less funds holding
Funds holding: 17 → 16 (-1)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
57% less capital invested
Capital invested by funds: $166K → $71.2K (-$95.2K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$7.65K |
| 2 |
Jane Street
New York
|
+$2.91K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$494 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$23 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$21.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$18.1K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$1.1K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$202 |
| 5 |
Morgan Stanley
New York
|
-$95 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Two Sigma Investments
New York
| $39.3K | -$21.6K | -31,970 | -29% |
|
|
XT
2
XTX Topco
George Town,
Cayman Islands
| $10.8K | +$7.65K | +11,348 | +103% |
|
|
3
Jane Street
New York
| $8.06K | +$2.91K | +4,310 | +36% |
|
|
TSS
4
Two Sigma Securities
New York
| $5.87K | -$1.1K | -1,631 | -12% |
|
|
5
Citadel Advisors
Miami,
Florida
| $5.5K | -$18.1K | -26,795 | -70% |
|
|
6
UBS Group
Zurich,
Switzerland
| $1.25K | +$494 | +732 | +40% |
|
|
7
BNP Paribas Financial Markets
Paris,
France
| $294 | -$202 | -300 | -33% |
|
|
8
Morgan Stanley
New York
| $77 | -$95 | -141 | -47% |
|
|
9
Wells Fargo
San Francisco,
California
| $21 | +$23 | +34 | +378% |
|
|
SS
10
SBI Securities
Tokyo,
Japan
| $8 | – | – | – |
|
|
FDCDDQ
11
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $7 | – | – | – |
|
12
Osaic Holdings
Scottsdale,
Arizona
| $2 | – | – | – |
|
|
AF
13
Allworth Financial
Folsom,
California
| $1 | – | – | – |
|
|
EWP
14
Elevation Wealth Partners
Santa Rosa,
California
| $1 | – | – | – |
|
15
Two Sigma Advisers
New York
| – | -$23.6K | -31,491 | Closed |
|
GLMD Hedge Fund Activity: Q1 2026 in Review
16 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2026, worth a combined $71.2K — down 57% from $166K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of GLMD and 0 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 4 added.
The largest buyer was XTX Topco, adding an estimated $7.65K. The largest seller was Two Sigma Investments, cutting an estimated $21.6K.
- 16 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2026, down from 17 in Q4 2025.
- Funds reported $71.2K of Galmed Pharmaceuticals stock for Q1 2026, down 57% quarter-over-quarter.
- 0 funds opened new Galmed Pharmaceuticals positions in Q1 2026 and 1 closed out, a net change of -1 holder.
- The largest Galmed Pharmaceuticals buyer in Q1 2026 was XTX Topco, an estimated $7.65K added.
- The largest Galmed Pharmaceuticals seller in Q1 2026 was Two Sigma Investments, an estimated $21.6K sold.
Based on aggregated 13F filings for Q1 2026.